A new study suggests that statins, a common medication for managing cardiovascular risk, may be linked to more severe menopause symptoms in postmenopausal women. The research, published on June 22, 2026, examined data from 1,184 postmenopausal women across nine Latin American countries.
Researchers compared women who used statins with those who did not, accounting for factors like age and body weight. The study assessed menopausal symptoms, risk of sarcopenia, and cognitive function. It is a cross-sectional study, meaning it can show associations but cannot prove that statins directly cause the observed outcomes.
Statin users were 56% more likely to report severe menopausal symptoms compared to non-users. They were also 65% more likely to be at risk for sarcopenia, the gradual loss of muscle mass and physical function that often accelerates after menopause due to declining estrogen levels. Muscle loss in this stage is linked to a higher risk of falls, fractures, and reduced quality of life.
Additionally, 53.1% of statin users reported intense musculoskeletal symptoms, compared to 33.9% of non-users. This finding points to a broader pattern of physical discomfort that may go unrecognized in women taking statins. On cognitive tests, statin users showed slightly lower scores on delayed memory recall and visuospatial function tests. No overall link to mild cognitive impairment was found, suggesting these are early signals to monitor rather than firm conclusions.
The researchers noted that statin-related effects may overlap with menopause symptoms, potentially compounding the burden women experience. They said untangling the two is an open area of research. The study does not recommend stopping statins, as their cardiovascular benefits are well-established. Instead, it offers a fuller picture of what statin therapy might mean for postmenopausal women, a group historically underrepresented in cardiovascular research.
Implications for patient care
For women on statins who find their menopause symptoms more intense than expected, or who notice changes in muscle strength or physical function, the study suggests raising these concerns with a doctor. Questions to consider include whether symptoms are consistent with statin use, whether screening for muscle loss is needed, if the current statin is the best option, and what steps can be taken to protect muscle health, such as resistance training and adequate protein intake.
The study adds to evidence that midlife women may benefit from more individualized care. Statins remain life-saving for many, but their side effects, particularly in postmenopausal women, deserve closer attention. The findings were published on mindbodygreen on June 22, 2026.
